Last update Feb. 12, 2019

Deferasirox

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Selective ferric iron chelator, orally active, used to treat chronic iron overload in the management of thalassemia and sickle cell anemia, whether transfusion-dependent or not.
The usual oral dose is 20 mg/kg/day taken daily.

Its pharmacokinetic data (very high percentage of plasma protein binding and moderately large volume of distribution) explain the zero transfer to milk observed: no traces of the drug were detected in the breastmilk of a 28-year-old mother with thalassemia major and taking a daily oral dose of 25 mg/kg (Giampetri 2018).

Nor were there growth problems or concentration of serum iron or ferritin in her infant child in any of the determinations during the first month of life (Giampetri 2018).

Until there is further published data on this drug in relation to breastfeeding, it may be advisable to monitor the serum iron level of the infant.

Alternatives

We do not have alternatives for Deferasirox since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Deferasirox in other languages or writings:

Tradenames

Main tradenames from several countries containing Deferasirox in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 70 %
Molecular weight 373 daltons
Protein Binding 99 %
VD 0.2 l/Kg
pKa 4.55 -
Tmax 1.5 - 4 hours
8 - 16 hours

References

  1. Giampreti A , Mattioli F, Faraoni L, Bedussia F, Spadac C, Galloa M, Eleftherioua G, Buteraa R, Bacia G. Lactation in beta-thalassemia major: Iis deferasirox compatible? The first case with clinical data and breastmilk concentrations. 38th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 22–25 May 2018, Bucharest, Romania. Clin Toxicol. 2018;56(6):539, Abstract 190. Clin Toxicol. 2018
  2. Novartis. Deferasirox. Drug Summary. 2018 Full text (in our servers)
  3. Novartis-EMA. Deferasirox. Ficha técnica. 2016 Full text (in our servers)

Total visits

2,178

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM